Report Overview

The Indian Human Insulin market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

India is second only to China in terms of diabetes burden. Among leading causes of death, diabetes was associated with the highest increase (XX %) in age-adjusted mortality in 2019. In India, some insulin products are listed on the national and state essential medicines lists (EMLs) for free-of-charge provision in the public-sector health facilities. Indias central and state public health systems are under-funded and offer limited healthcare coverage to the majority of the population. Increase in population suffering from diabetes due to the unhealthy lifestyle has caused the need for proper insulin drugs and delivery devices due to its resulting treatment of diabetes. Insulin is used for the treatment or control of rising sugar levels in the body caused by patients suffering from diabetes. Insulin drugs are either orally consumed or through delivery devices with the help of syringes, or needles. There is recent development in the market for inhaling of insulin through pumps, which is expected to drive the market growth due to the need for syringe free insulin delivery.



Market Drivers

High cases and increasing amount of diabetic patients, Advancements in the market and reimbursements procedures in developed regions is also expected to drive the market growth. The other factors, the genetic factors and sedentary lifestyle along with the geriatric population share of Chinese market is fueling the demand of Human insulin market in India. Also, insufficient competition of biosimilar products combined with the lack of trust of patients on biosimilar products is estimated to accelerate the demand of human insulin in India.